Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mirum PharmaceuticalsMEX:MIRM 46 3-Year ROIIC % is 63.22 as of Dec. 2025, which is 161% above its 10-year median of 24.21. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN872.87. The stock has 6 warning signs investors should review. Among 1,322 Biotechnology companies, Mirum Pharmaceuticals ranks better than 74.13% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Mirum Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 63.22%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Mirum Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
MEX:MIRM's 3-Year ROIIC % is ranked better than 74.13% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs MEX:MIRM: 63.22
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Mirum Pharmaceuticals 3-Year ROIIC % Related Terms
Mirum Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MIRM vs RYTM, SYRE, PTGX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Mirum Pharmaceuticals (MEX:MIRM) has a 3-Year ROIIC % of 63.22 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mirum Pharmaceuticals and its competitors. This is 161% above median its historical median of 24.21. According to the industry distribution chart, Mirum Pharmaceuticals ranks #342 out of 1322 companies in the Biotechnology industry, placing it in the top 25.9%.
Is Mirum Pharmaceuticals' 3-Year ROIIC % too high?
Mirum Pharmaceuticals' current 3-Year ROIIC % of 63.22 is 161% above median its 10-year median of 24.21. Based on the distribution chart, Mirum Pharmaceuticals ranks #342 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' 3-Year ROIIC % compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #342 out of 1322 companies for 3-Year ROIIC %. This puts Mirum Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current 3-Year ROIIC % is 63.22, which is 161% above median its own 10-year median of 24.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current 3-Year ROIIC % of 63.22. The stock's GF Value™ is MXN872.87, compared to a current price of MXN1,256.12 — trading 43.9% above its estimated fair value. The current 3-Year ROIIC % is 63.22, which is 161% above median its 10-year median of 24.21. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current 3-Year ROIIC % is 63.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,256.12 is trading 43.9% above its estimated GF Value™ of MXN872.87.
Key valuation signals for MEX:MIRM:
3-Year ROIIC %: 63.22 (161% above median its 10-year median of 24.21)
GF Value™: MXN872.87 vs. price of MXN1,256.12 (43.9% above fair value)
No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score
Get the complete analysis for MEX:MIRM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MIRM has been successfully added to your 
